BIOMAT Database Logo BIOMAT Database Logo

[Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension]. 2001

N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Division of Cardiology, Department of Medicine, National Cardiovascular Center, Fujishirodai 5-7-1, Suita, Osaka 565-8565.

BACKGROUND Plasma brain natriuretic peptide (BNP) level increases in proportion to the degree of right ventricular dysfunction in pulmonary hypertension. We sought to assess the prognostic significance of plasma BNP in patients with primary pulmonary hypertension. RESULTS Plasma BNP was measured in 60 patients with primary pulmonary hypertension at diagnostic catheterization, together with atrial natriuretic peptide, norepinephrine, and epinephrine. Measurements were repeated in 53 patients after a mean follow-up period of 3 months. Forty-nine of the patients received intravenous or oral prostacyclin. During a mean follow-up period of 24 months, 18 patients died of cardiopulmonary causes. According to multivariate analysis, baseline plasma BNP was an independent predictor of mortality. Patients with a supramedian level of baseline BNP (> or = 150 pg/ml) had a significantly lower survival rate than those with an inframedian level, according to Kaplan-Meier survival curves (p < 0.05). Plasma BNP in survivors decreased significantly during the follow-up (217 +/- 38 to 149 +/- 30 pg/ml, p < 0.05), whereas that in nonsurvivors increased (365 +/- 77 to 544 +/- 68 pg/ml, p < 0.05). Thus, survival was strikingly worse for patients with a supramedian value of follow-up BNP (> or = 180 pg/ml) than for those with an inframedian value (p < 0.0001). CONCLUSIONS A high level of plasma BNP, and in particular, a further increase in plasma BNP during follow-up, may have a strong, independent association with increased mortality in patients with primary pulmonary hypertension.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D020097 Natriuretic Peptide, Brain A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. Brain Natriuretic Peptide,Nesiritide,B-Type Natriuretic Peptide,BNP Gene Product,BNP-32,Brain Natriuretic Peptide-32,Natrecor,Natriuretic Factor-32,Natriuretic Peptide Type-B,Type-B Natriuretic Peptide,Ventricular Natriuretic Peptide, B-type,BNP 32,Brain Natriuretic Peptide 32,Natriuretic Factor 32,Natriuretic Peptide Type B,Natriuretic Peptide, B-Type,Natriuretic Peptide, Type-B,Natriuretic Peptide-32, Brain,Peptide, Brain Natriuretic,Peptide-32, Brain Natriuretic,Type B Natriuretic Peptide,Ventricular Natriuretic Peptide, B type

Related Publications

N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
May 2006, Chest,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
[Brain natriuretic peptide in primary pulmonary hypertension].
March 2006, Revista medica de Chile,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.
April 2009, Internal and emergency medicine,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.
March 2004, Journal of the American College of Cardiology,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
May 2014, Respirology (Carlton, Vic.),
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Raised plasma concentrations of brain natriuretic peptide in pulmonary arterial hypertension.
July 1995, Respiratory medicine,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease.
June 2012, Lung,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Atrial natriuretic peptide in primary pulmonary hypertension.
September 1990, The European respiratory journal,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
Raised brain natriuretic peptide in pulmonary hypertension.
April 1996, Respiratory medicine,
N Nagaya, and T Nishikimi, and M Uematsu, and T Satoh, and S Kyotani, and F Sakamaki, and M Kakishita, and K Fukushima, and Y Okano, and N Nakanishi, and K Miyatake, and K Kangawa
N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension.
April 2009, Transplantation proceedings,
Copied contents to your clipboard!